Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Sawai to buy Upsher-Smith’s generic pharmaceuticals business for $1.05bn Japan-based Sawai Pharmaceutical has agreed to acquire Upsher‐Smith’s generic pharmaceuticals business from its parent firm Acova for around $1.05bn. Production & Manufacturing > Process & Production > News
AbbVie's pan-genotypic HCV regimen achieves 99% cure rate in phase 3 study By PBR Staff Writer
A phase 3 study demonstrated that AbbVie's pan-genotypic ribavirin-free HCV regimen of glecaprevir/pibrentasvir (G/P) achieved a 99% cure rate after 12 weeks of treatment.
Contract Research & Services > Clinical Trials > News H3 Biomedicine, Foundation Medicine extend precision oncology collaboration H3 Biomedicine has extended its multi-year collaboration, which was signed in February 2015, with Foundation Medicine to discover and develop precision medicines in oncology.
Drug Research > Drug Discovery & Development > News Immune Pharmaceuticals licenses cancer treatment's Latin America rights to Pint Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.
Contract Research & Services > Contract Services > News
Sawai to buy Upsher-Smith’s generic pharmaceuticals business for $1.05bn By PBR Staff Writer
Japan-based Sawai Pharmaceutical has agreed to acquire Upsher‐Smith’s generic pharmaceuticals business from its parent firm Acova for around $1.05bn.
Production & Manufacturing > Process & Production > News Novartis signs collaboration deal with Parvus for diabetes nanomedicine By PBR Staff Writer
Pharma giant Novartis has acquired the exclusive, worldwide rights for Parvus Therapeutics’ Navacim technology for type 1 diabetes (T1D) treatment.
Drug Research > Drug Discovery & Development > News Ultragenyx's hypophosphatemia drug succeeds in phase 3 study Ultragenyx Pharmaceutical, Kyowa Hakko Kirin and Kyowa Kirin International have reported positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 trial of burosumab (KRN23) in X-linked hypophosphatemia (XLH) adult patients.
Contract Research & Services > Clinical Trials > News

Latest News and Insight by Sector

Production & Manufacturing

Sawai to buy Upsher-Smith’s generic pharmaceuticals business for $1.05bn
By PBR Staff Writer
Japan-based Sawai Pharmaceutical has agreed to acquire Upsher‐Smith’s generic pharmaceuticals business from its parent firm Acova for around $1.05bn.
Production & Manufacturing > Process & Production > News
Novartis gets FDA breakthrough therapy status for CTL019 to treat r/r DLBCL
By PBR Staff Writer
Novartis has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its investigational chimeric antigen receptor T cell (CAR-T) therapy, CTL019, to treat adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies.
Production & Manufacturing > Process & Production > News

Drug Research

H3 Biomedicine, Foundation Medicine extend precision oncology collaboration
H3 Biomedicine has extended its multi-year collaboration, which was signed in February 2015, with Foundation Medicine to discover and develop precision medicines in oncology.
Drug Research > Drug Discovery & Development > News
Novartis signs collaboration deal with Parvus for diabetes nanomedicine
By PBR Staff Writer
Pharma giant Novartis has acquired the exclusive, worldwide rights for Parvus Therapeutics’ Navacim technology for type 1 diabetes (T1D) treatment.
Drug Research > Drug Discovery & Development > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

AbbVie's pan-genotypic HCV regimen achieves 99% cure rate in phase 3 study
By PBR Staff Writer
A phase 3 study demonstrated that AbbVie's pan-genotypic ribavirin-free HCV regimen of glecaprevir/pibrentasvir (G/P) achieved a 99% cure rate after 12 weeks of treatment.
Contract Research & Services > Clinical Trials > News
Immune Pharmaceuticals licenses cancer treatment's Latin America rights to Pint
Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.
Contract Research & Services > Contract Services > News

Automation

Accenture, BioCelerate partner to advance biopharmaceutical innovation
Accenture and TransCelerate BioPharma's subsidiary BioCelerate have partnered to advance biopharmaceutical innovation through increased insights in research & development.
Automation > IT & Software > News
IBM scientists secure patent on machine learning models for drug discovery
By PBR Staff Writer
Technology giant IBM has secured a patent on machine learning models for drug discovery.
Automation > IT & Software > News

Regulatory Affairs

Genentech’s ranibizumab injection approved by FDA for diabetic retinopathy
The US Food and Drug Administration (FDA) has approved Genentech’s Lucentis (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy.
Regulatory Affairs > News
FDA reject’s Eli Lilly’s NDA for rheumatoid arthritis drug baricitinib
By PBR Staff Writer
The US Food and Drug Administration has rejected Eli Lilly and Incyte’s new drug application (NDA) for investigational medicine baricitinib to treat moderate-to-severe rheumatoid arthritis (RA).
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery